Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
CX-4945
120
CHF
CHF 120.00
In stock
SYN-1109-M0011 mgCHF 120.00
SYN-1109-M0055 mgCHF 198.00
SYN-1109-M01010 mgCHF 329.00
SYN-1109-M05050 mgCHF 988.00
SYN-1109-M100100 mgCHF 1'646.00
| Product Details | |
|---|---|
| Synonyms | CX4945 |
| Product Type | Chemical |
| Properties | |
| Formula | C19H12ClN3O2 |
| MW | 349.8 |
| CAS | 1009820-21-6 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: Chk2 | Kinase Group: CAMK | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | MUOKSQABCJCOPU-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
CX-4945 is a first-in-class, orally active, potent and selective inhibitor of the protein kinase CK2, with an IC(50) of 1nM.
Product References
- Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer: F. Pierre, et al.; J. Med. Chem. 54, 635 (2011)
Related Products
